Cannabix Puts BreathLogix Into a Montana County Jail
Cannabix Technologies placed its BreathLogix alcohol screening unit at a Big Horn County, Montana detention center under the state's 24/7 Sobriety Program. The shares, quoted at 0.38, rose 2.98%.
Cannabix Technologies Inc. said on August 20, 2026 that it has deployed its BreathLogix alcohol screening system with Big Horn County Misdemeanor Probation and Pre-trial Services in Montana, sited at the county detention center and run by probation staff under the state's 24/7 Sobriety Program.
Cannabix Technologies Inc., the breath-testing developer quoted under the symbol BLOZF, said on August 20, 2026 that its BreathLogix alcohol screening system has gone into service with Big Horn County Misdemeanor Probation and Pre-trial Services in Montana. The unit sits at the county detention center and is overseen by the misdemeanor probation and pre-trial staff, and it operates under Montana's statewide 24/7 Sobriety Program.
That is the whole of the announced fact set. No contract value, unit count or term was disclosed, which is itself the most useful thing an investor can take from the release: this is a placement, not a purchase order with a number attached to it. The company's own framing — a deployment "with" a county department — describes a device installed and operating, not a multi-site rollout.
What a 24/7 Sobriety placement actually involves
Montana's 24/7 Sobriety Program is a court-supervised regime in which people on probation or awaiting trial, typically after alcohol-related offenses, submit to repeated breath testing rather than sitting in custody. The defining feature is frequency. Participants report on a fixed schedule, often twice daily, and a failed or missed test triggers a swift consequence. The model depends on testing being cheap, fast and hard to argue with, because the volume of tests per participant is high and the administrative burden falls on a small county staff.
That is the operational niche BreathLogix is being sold into. Placing the device at a detention center, supervised by probation officers rather than lab technicians, tells you the product is being positioned as a self-service or lightly-attended screening station — something a participant walks up to, uses, and leaves a record behind on. The customer in this case is a county misdemeanor unit, one of the smaller buying entities in the criminal-justice supply chain.
Why the absence of a dollar figure matters
Cannabix is best known for its work on marijuana breath detection, a technically harder problem that has kept the company in development mode for years. BreathLogix, the alcohol product, is the nearer-term commercial vehicle, and announcements of the kind published through BNN Bloomberg are how a pre-revenue or early-revenue device maker demonstrates that a product has left the bench.
The distinction worth holding onto is between reference sites and revenue. A single county department can be a reference site — proof that a state program administrator accepted the device, that the workflow survived contact with real supervisees, that the data output satisfied a court. Reference sites are genuinely valuable, because government buyers rarely adopt a screening technology that no peer agency has already run. But a reference site is not a run-rate. Until Cannabix discloses units shipped, per-test pricing, or a recurring service agreement, no one outside the company can size what this is worth.
What would change that assessment is repetition. If further Montana counties follow, or if the program administrator standardizes on the device, the individual placements stop being pilots and start looking like a channel. Investors watching this name should count deployments over the next several announcements and note whether the language shifts from "deployment" to "contract," "purchase order" or "agreement" with terms.
How the shares traded on the day
BLOZF changed hands at 0.38 as of the last trade at 17:59 GMT on August 20, 2026, up 2.98% from the prior close of 0.37, with a day range of 0.37 to 0.39. The quote feed carried the price without an identified currency or exchange, which is common for thinly traded over-the-counter lines and is worth flagging rather than assuming.
The move came against a broadly negative session in U.S. equities. The S&P 500 tracker SPY traded at $764.68, down 0.57%; the Nasdaq 100 proxy QQQ was at $710.82, off 0.73%; and the Dow tracker DIA fell 1.01% to $528.87. A sub-dollar micro-cap rising on news while the major averages sagged is not, on its own, a signal about the business. At this price level, a single cent of movement is a large percentage, spreads are wide relative to the quote, and the day's high and low sit within a two-cent band. Position sizing, not thesis strength, is the operative risk for a security priced this way.
The commercialization question this does not settle
A sub-dollar micro-cap rising on news while the major averages sagged is not, on its own, a signal about the business.
Cannabix has two product lines with very different regulatory paths. Alcohol breath testing is a mature, legally settled field: courts accept breath alcohol evidence, the measurement is well understood, and the competitive set includes established instrument makers with long-standing agency relationships. Winning there is a matter of price, reliability and service, not of proving the science.
Marijuana breath detection is the opposite. There is no settled per-se impairment standard tied to a breath measurement, and adoption depends on legal frameworks that vary by state. A company selling into criminal justice needs its output to survive challenge in court, and that hurdle has slowed the entire cannabis-breathalyzer field.
Seen that way, the Montana placement is best read as progress on the easier of the two paths — getting hardware into an agency, learning how supervision staff use it, and building the kind of institutional references that later support a harder sell. It does not tell you anything new about the marijuana device.
What to watch next
- Whether Cannabix follows with additional Montana counties, or with other states running comparable 24/7-style sobriety supervision programs.
- Any disclosure of commercial terms — unit price, per-test fees, service contracts or subscription revenue — which would let outsiders model the opportunity instead of guessing at it.
- The company's next financial filing, and specifically whether BreathLogix shows up as recognized revenue rather than as a line in a press release.
- Any movement on the marijuana breath product's evidentiary or regulatory standing, which remains the larger and more speculative part of the story.
For now, the honest summary is narrow: one device, one county detention center, one state program, no stated dollars. That is a step, and small companies are built out of steps. It is not yet a business model that anyone outside the company can measure.
Key facts
- Symbol and price: BLOZF at 0.38, +2.98%, as of 17:59 GMT Aug 20, 2026 (currency not specified by quote feed)
- Deployment: BreathLogix alcohol screening system at Big Horn County detention center, Montana
- Program: Montana's state 24/7 Sobriety Program, overseen by misdemeanor probation and pre-trial staff
- Financial terms: None disclosed — no contract value, unit count or duration announced
Frequently asked questions
What did Cannabix Technologies announce?
On August 20, 2026, Cannabix Technologies said it had deployed its BreathLogix alcohol screening solution with Big Horn County Misdemeanor Probation and Pre-trial Services in Montana. The system is located at the county detention center and is overseen by misdemeanor probation and pre-trial staff, operating under Montana's statewide 24/7 Sobriety Program.
How much revenue does the deployment generate?
The company did not disclose any financial terms. No contract value, number of units, per-test pricing or agreement duration was included in the announcement. Without those details, outside investors cannot size the placement's contribution, and it should be treated as a reference installation rather than as quantified revenue until the company reports otherwise.
What is Montana's 24/7 Sobriety Program?
It is a court-supervised program in which people on probation or awaiting trial, typically following alcohol-related offenses, submit to frequent breath testing instead of remaining in custody. Testing is often scheduled multiple times per day, and missed or failed tests bring swift consequences, so the program depends on screening equipment that is fast, inexpensive and simple for staff to supervise.
How did Cannabix shares trade on the news?
The BLOZF quote was 0.38 as of the last trade at 17:59 GMT on August 20, 2026, up 2.98% from a previous close of 0.37, within a day range of 0.37 to 0.39. The quote feed did not identify the currency or exchange. The gain came while U.S. benchmark trackers SPY, QQQ and DIA were all lower on the day.
How does BreathLogix differ from Cannabix's marijuana device?
BreathLogix targets alcohol screening, a legally settled field where breath measurement is accepted by courts and competition turns on price, reliability and service. The company's marijuana breath detection work faces a harder path, because impairment standards tied to a breath measurement are not uniformly established and adoption depends on state-by-state legal frameworks.
What should investors watch from here?
Look for additional county or state placements that would turn one-off deployments into a repeatable sales channel, any disclosure of commercial terms such as unit pricing or service fees, and whether BreathLogix appears as recognized revenue in the company's next financial filing. Progress on the marijuana device's evidentiary standing is a separate and longer-dated question.
Sources
Photo: Rodolfo Gaion · Pexels Licence — source
